



# BEATBio

## BEAT BioTherapeutic's co-founder, Dr. Michael Regnier, to present at International Society for Heart Research Meeting

**(SEATTLE, WA) May 12, 2014** – BEAT BioTherapeutics Corporation (BEATBio) announced today that co-founder and Scientific Advisory Board member, Dr. Michael Regnier, will present at the upcoming International Society for Heart Research (ISHR) annual meeting on May 14, 2014 in Miami Beach, FL. Dr. Regnier will speak about his research showing that deoxy-ATP (dATP) may enhance cardiac performance in heart failure. This research supports the efforts of BEATBio to develop BB-R12, an exciting new therapy for heart failure that increases cardiac levels of dATP. ISHR is a prominent international group of researchers and clinicians with a key interest in promoting research in cardiovascular biology and therapeutics. Dr. Regnier is Professor and Vice Chairman of the Department of Bioengineering at the University of Washington. He also leads the Heart and Muscle Mechanics laboratory in the Department of Bioengineering and is an expert in cardiac and skeletal muscle physiology, muscle dysfunction with disease and development of gene and cell therapies. Dr. Regnier is part of a multi-disciplinary team at BEATBio developing BB-R12. Dr. Regnier's presentation is titled "*AAV6-mediated overexpression of Ribonucleotide Reductase (R1R2) increases myocardial dATP and improves function of normal and failing hearts*". His presentation is part of the ISHR's Metabolism Session.

**About BEATBio:** BEATBio is a Seattle, WA-based biotechnology company focused on the development of a novel biological treatment for heart failure. BB-R12 therapy is based on the fundamental discovery that dATP is a superior fuel for cardiac muscle contraction than is ATP. BB-R12 is being developed to treat heart failure by increasing cardiac performance. BEATBio's founders, from the University of Washington, are recognized experts in cardiovascular biology, muscle physiology and bioengineering and have received nearly \$50MM of NIH funding. BEATBio holds worldwide rights to this technology and used a recently raised \$2.9MM seed financing to successfully complete the initial stages of pre-clinical development and manufacturing scale-up. BEATBio has assembled a strong team of experts that allowed rapid achievement of significant development milestones in 2013. The company is now raising a Series A financing to complete IND-enabling studies and commence Phase I human trials.

### Contact:

Michael Kranda, CEO

[mkranda@BEATBiotherapeutics.com](mailto:mkranda@BEATBiotherapeutics.com)

(M) 425-647-4236

Gregory Mahairas, CSO

[gmahairas@BEATBiotherapeutics.com](mailto:gmahairas@BEATBiotherapeutics.com)

(M) 206 295-7905

Sam L. Teichman, CMO

[steichman@BEATBiotherapeutics.com](mailto:steichman@BEATBiotherapeutics.com)

(M) 925 437-2067